MCW Cancer Center logo

Funding and Grants

Current Funding Opportunities

National Cancer Institute (NCI)

Open AllClose All
  Limited Competition: The Chernobyl Tissue Bank – Coordinating Center (U24) (Deadline: 1/20/17)

Limited Competition: The Chernobyl Tissue Bank – Coordinating Center (U24)

This limited competition Funding Opportunity Announcement solicits the renewal application for the Chernobyl Tissue Bank Coordinating Center.

The Chernobyl Tissue Bank is a collaborative resource that is supported by the National Cancer Institute and another international partner and includes active participation of countries critically affected by the Chernobyl nuclear power plant accident. The objective of the Chernobyl Tissue Bank is to maintain a research resource that supports current and future studies on the biology of thyroid cancer, a major health consequence of the Chernobyl accident. The Chernobyl Tissue Bank Coordinating Center is the critical infrastructure that serves this goal and functions to lead, plan, integrate, and achieve the stated research objectives in collaboration with the participating institutions in the Chernobyl-affected countries.

Applications due January 20, 2017

  National Cancer Institute Program Project Applications (P01) (Deadline: 1/25/17)

National Cancer Institute Program Project Applications (P01)

With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.

Applications due January 25, 2017

  National Cancer Institute Youth Enjoy Science Research Education Program (R25) (Deadline: 1/25/17)

National Cancer Institute Youth Enjoy Science Research Education Program (R25)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The over-arching goal of this National Cancer Institute (NCI)  R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce.

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences, Curriculum or Methods Development and Outreach. The NCI’s mission is to conduct and support research, training, health information dissemination, and other programs with respect to cancer. This funding opportunity seeks to facilitate the education of students from diverse backgrounds underrepresented in biomedical research who will become knowledgeable about cancer, and available to focus on cancer later in their careers. With the aim of enhancing the pool of individuals from underrepresented backgrounds interested in pursuing a career in biomedical research via early intervention strategies, the NCI Youth Enjoy Science (YES) Program will support efforts to create and maintain an institutional program to engage grades 6-12 and/or undergraduate students from underrepresented populations in cutting edge cancer research experiences. The proposed institutional programs may also provide research experiences for the grade 6-12 teachers and undergraduate faculty members who serve underrepresented student populations.

The specific goals are to inspire interest in biomedical sciences, help envision research as a career path, and strengthen practical research and career skills. In alignment with these goals, institutions may develop unique programs that capitalize on their research strengths and are responsive to their target populations.

Applications due January 25, 2017

  Support of Competitive Research (SCORE) Research Advancement Award (SC1) (Deadline: 1/25/17)

Support of Competitive Research (SCORE) Research Advancement Award (SC1)

The SCORE Program is a developmental program designed to increase the research competitiveness of faculty and the research base at institutions with an explicitly stated historical mission and/or a demonstrated historical track record of training and graduating students from backgrounds underrepresented in biomedical research. Eligible institutions must award science degrees to undergraduate (BS or BA) and/or graduate students (MS or PhD) and have received less than six million dollars per year of NIH R01 support (total costs) in each of the last two fiscal years.

Applications due January 25, 2017

  Support of Competitive Research (SCORE) Pilot Project Award (SC2) (Deadline: 1/25/17)

Support of Competitive Research (SCORE) Pilot Project Award (SC2)

The SCORE Program is a developmental program designed to increase the research competitiveness of faculty and research capacity of institutions with an explicitly stated historical mission and/or a demonstrated historical track record of training and graduating students from backgrounds underrepresented in biomedical research. Eligible institutions must award science degrees to undergraduate (BS or BA) and/or graduate students (MS or PhD) and have received less than six million dollars per year of NIH R01 support (total costs) in each of the last two fiscal years.

Applications due January 25, 2017

  Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2015, 2016, and 2017 (P50) (Deadline: 1/27/17)

Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2015, 2016, and 2017 (P50)

This Funding Opportunity Announcement (FOA) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPOREs). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer (or a related group of cancers). For the purpose of this funding announcement, cancers derived from the same organ system (i.e., group of organs that perform common function) are considered related. Examples of such organ systems include gastro-intestinal, endocrine, circulatory, and other biological systems. Other programmatically appropriate groups of cancers may include those centered around a common biological mechanism critical for promoting tumorigenesis and/or cancer progression in organ sites that belong to different organ systems.

For example, a SPORE may focus on cancers caused by the same infectious agent, or sustained and promoted by dysregulation of a common signaling pathway. SPOREs are expected not only to conduct a wide spectrum of research activities, but also to contribute significantly to the development of specialized shared resources core facilities, improved research model systems, and collaborative research projects with other institutions.

The research supported through this program must be translational in nature and must always be focused upon knowledge of human biology stemming from research using cellular, molecular, structural, biochemical, and/or genetic experimental approaches with the goal of a translational human endpoint within the project period of the grant. In addition, SPOREs must include both a Developmental Research Program for pilot studies and a Career Enhancement Program to foster careers in translational research related to the focus of the SPORE.

Applications due January 27, 2017

  Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R21) (Deadline: 2/1/17)

Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R21)

The purpose of this funding opportunity announcement (FOA) is to encourage exploratory/developmental research grant applications to: (1) assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; (2) identify structural, systemic, and psychosocial barriers to adherence; and (3) develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized.

Applications should focus research questions on at least one of the following: specific cancer type; class of drugs; and/or groups subject to disparities (e.g., elderly populations, members of low socioeconomic groups, racial/ethnic minorities). Research may be focused at the patient (pediatric, adolescent, or adult), patient-caregiver, provider, health care team, or health care delivery system level, and may include intervention studies, observational studies, or mixed-methods studies.

Observational studies should emphasize modifiable risk factors for future intervention research.

Applications due February 1, 2017

  NCI Research Specialist (Core-based Scientist) Award (R50) (Deadline: 2/2/17)

NCI Research Specialist (Core-based Scientist) Award (R50)

This Funding Opportunity Announcement (FOA) invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for core/shared resource/central scientific support scientists.

The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical or population science cancer research program, but not serve as independent investigators. These scientists, such as researchers within a core/shared resource/central scientific support, are vital to sustaining the biomedical research enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others for career continuity.

Applications due February 2, 2017

  NCI Research Specialist (Laboratory-based Scientist) Award (R50) (Deadline: 2/2/17)

NCI Research Specialist (Laboratory-based Scientist) Award (R50)

This Funding Opportunity Announcement (FOA) invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for laboratory-based scientists.

The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical or population science cancer research program, but not serve as independent investigators. These scientists, such as researchers within a research program, are vital to sustaining the biomedical research enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others for career continuity.

Applications due February 2, 2017

  Addressing Health Disparities through Effective Interventions Among Immigrant Populations (R01) (Deadline: 2/5/17)

Addressing Health Disparities through Effective Interventions Among Immigrant Populations (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research to develop and implement effective interventions to address health disparities among U.S. immigrant populations.

Applications due February 5, 2017

  Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations (R01) (Deadline: 2/5/17)

Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research to understand uniquely associated factors (biological, behavioral, sociocultural, and environmental) that contribute to health disparities or health advantages among U.S. immigrant populations.

Applications due February 5, 2017

  Examination of Survivorship Care Planning Efficacy and Impact (R01) (Deadline: 2/5/17)

Examination of Survivorship Care Planning Efficacy and Impact (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes. How organizational-level factors influence the implementation of care planning and its associated costs is also of interest.

Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evaluating the impact of survivorship care planning; 2) evaluate the impact of survivorship care planning on cancer survivors' morbidity, self-management and adherence to care recommendations, utilization of follow-up care; 3) evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organizations implementing the care planning; and 4) identify models and processes of care that promote effective survivorship care planning.

The ultimate goal of this FOA is to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors.

Applications due February 5, 2017

  Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01) (Deadline: 2/5/17)

Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01)

This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiac risk prior to treatment and integrate evidence-based cancer treatment regimens with screening, diagnostic, and/or management strategies are sought. Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term survivorship) as defined by cardiac specific common terminology criteria for adverse events (CTCAE).

Components of Participating Organizations:

  • National Cancer Institute (NCI)
  • National Heart, Lung, and Blood Institute (NHLBI)

Applications due February 5, 2017

  Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R01) (Deadline: 2/5/17)

Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R01)

The purpose of this funding opportunity announcement (FOA) is to encourage research grant applications to: (1) assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; (2) identify structural, systemic, and psychosocial barriers to adherence; and (3) develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized.

Applications should focus research questions on at least one of the following: specific cancer type; class of drugs; and/or groups subject to disparities (e.g., elderly populations, members of low socioeconomic groups, racial/ethnic minorities). Research may be focused at the patient (pediatric, adolescent, or adult), patient-caregiver, provider, health care team, or health care delivery system level, and may include intervention studies, observational studies, or mixed-methods studies.

Observational studies should emphasize modifiable risk factors for future intervention research.

Applications due February 5, 2017

  Potential Effects of Metformin on Aging and Age-Related Conditions: Small-Scale Clinical Studies and Secondary Analysis of Controlled Clinical Studies (R01) (Deadline: 2/5/17)

Potential Effects of Metformin on Aging and Age-Related Conditions: Small-Scale Clinical Studies and Secondary Analysis of Controlled Clinical Studies (R01)

Data from clinical studies of metformin in a variety of patient populations suggest that it may have other effects, besides being an antihyperglycemic agent, which warrant further attention in translational aging research. The objective of this FOA is to support research projects (R01), including small-scale physiologic studies in humans or secondary analyses of data and/or stored biospecimens from controlled clinical intervention studies, to increase our understanding of the clinical translational potential of metformin to delay deleterious aging changes or to extend healthy human life span.  This includes identification of specific populations particularly likely to benefit from treatment, and/or obtaining information on metformin’s human physiologic and cellular effects that would be useful in identifying novel molecular targets.  

Applications due February 5, 2017

  Research Aimed at Novel Behavioral Targets to Improve Adolescent Substance Abuse Treatment and Prevention Interventions (R01) (Deadline: 2/5/17)

Research Aimed at Novel Behavioral Targets to Improve Adolescent Substance Abuse Treatment and Prevention Interventions (R01)

This Funding Opportunity Announcement (FOA) is part of a trans-NIH initiative known as Collaborative Research on Addiction at NIH (CRAN). Areas supported by this FOA include research to inform the generation and refinement of novel targets for substance abuse treatment and prevention interventions, modules or adjuncts to existing treatments and prevention interventions that seek to target and modulate behavioral or neurobehavioral processes (e.g., impulsivity, risk-taking propensity, sensation and novelty seeking, distress tolerance, delay discounting, self-regulation, stress reactivity) in adolescents. Additionally, this FOA will encourage studies to include theoretical links that explore the relationship(s) between neural circuitry and treatment and prevention effects, and in particular, how behavioral targets might be affected by treatment and prevention interventions, and how that might be used to improve targeted treatment and prevention intervention development, that translate to reduced morbidity and mortality.

Components of Participating Organizations:
National Institute on Drug Abuse (NIDA)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Cancer Institute (NCI)

Applications due February 5, 2017

  Coordinating Center for Population-Based Research to Optimize the Screening Process (PROSPR) (U24) (Deadline: 2/9/17)

Coordinating Center for Population-Based Research to Optimize the Screening Process (PROSPR) (U24)

The overall goal for the PROSPR Research Centers is to enhance understanding of the implementation and effects of screening as practiced in multiple healthcare environments in the United States.

The intent of this FOA is to fund a single Coordinating Center that will support a network of three PROSPR Research Centers (PRCs; one each focused on cervical, colorectal, and lung cancer). Specifically, the Coordinating Center will facilitate the development of common measures across cancer types for (1) system-level factors that may impact the cancer screening process, and (2) quality of screening. It will also coordinate PROSPR network research projects that include more than one cancer type. Finally, the Coordinating Center will be responsible for developing and implementing a process for PROSPR data access and sharing with qualified investigators outside of the PROSPR network.

Applications due February 9, 2017

  Population-Based Research to Optimize the Screening Process (PROSPR) (UM1) (Deadline: 2/9/17)

Population-Based Research to Optimize the Screening Process (PROSPR) (UM1)

The overall goal for PROSPR Research Centers is to enhance understanding of the implementation and effects of screening as practiced in multiple, heterogeneous healthcare environments in the United States. Therefore, the research programs proposed must cover long-term observations of diverse cohorts of patients who are eligible for screening. In addition to observational research to evaluate factors that affect the quality of the screening process for the selected cancer type, these programs should also develop and pilot-test interventions aimed at improving the screening process for that cancer.

It is expected that this FOA will support one PROSPR Research Center for each of the three cancer types: cervical, colorectal, and lung cancer. Each proposed Research Center must be entirely focused on screening for one of these three eligible cancer types.

In addition, PROSPR Research Centers to be proposed must be able to study the cancer screening processes in at least three different healthcare systems. Therefore, appropriate collaborative arrangements with providers of screening/diagnostic services are required.

Applications due February 9, 2017

  NCI Transition Career Development Award to Promote Diversity (K22) (Deadline: 2/12/17)

NCI Transition Career Development Award to Promote Diversity (K22)

The purpose of the NCI Career Transition Award to Promote Diversity program is to assist a postdoctoral fellow's transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. To this end, the Diversity Training Branch (DTB), the Center to Reduce Cancer Health Disparities (CRCHD) (http://crchd.cancer.gov/) invites applications from research scientists in postdoctoral positions or equivalent who are from backgrounds underrepresented in biomedical, behavioral, clinical, and/or social sciences. This award will provide "protected time" through salary and research support for 3 years for recipients to develop and receive support for their initial cancer research program. 

Applications due February 12, 2017

  Administrative Supplement for Research on Sex/Gender Influences (Admin Supp) (Deadline: 2/13/17)

Administrative Supplement for Research on Sex/Gender Influences (Admin Supp)

The Office of Research on Women's Health (ORWH) announces the availability of administrative supplements to support research highlighting the impact of sex/gender influences and/or sex and gender factors in human health and illness, including basic, preclinical, clinical and behavioral studies. Of special interest are studies relevant to understanding the significance of biological sex on cells and tissue explants; comparative studies of male and female tissues, organ systems and physiological systems; sex-based comparisons of pathophysiology, biomarkers, gene expression, clinical presentation and prevention and treatment of diseases.

The most robust experimental designs include consideration of both sex and gender; therefore, applications proposing to investigate the influence of both sex and gender factors are highly encouraged. The proposed research must address at least one objective from Goals 1 through 3 of the NIH Strategic Plan for Women's Health Research.

Applications due February 13, 2017

  Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01) (Deadline: 2/15/17)

Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01)

This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data.

This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.

Applications due February 15, 2017

  Addressing Health Disparities through Effective Interventions Among Immigrant Populations (R21) (Deadline: 2/16/17)

Addressing Health Disparities through Effective Interventions Among Immigrant Populations (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to support and accelerate innovative exploratory and developmental research to develop and test feasibility of effective interventions to address health disparities among U.S. immigrant populations.

Applications due February 16, 2017

  Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations (R21) (Deadline: 2/16/17)

Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research to understand uniquely associated factors (biological, behavioral, sociocultural, and environmental) that contribute to health disparities or health advantages among U.S. immigrant populations.

Applications due February 16, 2017

  Examination of Survivorship Care Planning Efficacy and Impact (R21) (Deadline: 2/16/17)

Examination of Survivorship Care Planning Efficacy and Impact (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate developmental research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes. How organizational-level factors influence the implementation of care planning and its associated costs is also of interest.

Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evaluating the impact of survivorship care planning; 2) evaluate the impact of survivorship care planning on cancer survivors' morbidity, self-management and adherence to care recommendations, utilization of follow-up care; 3) evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organizations implementing the care planning; and 4) identify models and processes of care that promote effective survivorship care planning. The ultimate goal of this FOA is to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors.

Applications due February 16, 2017

  Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21) (Deadline: 2/16/17)

Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21)

This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiac risk prior to treatment and integrate evidence-based cancer treatment regimens with screening, diagnostic, and/or management strategies are sought. Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term survivorship) as defined by cardiac specific common terminology criteria for adverse events (CTCAE).

Components of Participating Organizations:

  • National Cancer Institute (NCI)
  • National Heart, Lung, and Blood Institute (NHLBI)

Applications due February 16, 2017

  Palliative Care Needs of Individuals With Rare Advanced Diseases and Their Family Caregivers (R21) (Deadline: 2/16/17)

Palliative Care Needs of Individuals With Rare Advanced Diseases and Their Family Caregivers (R21)

This funding opportunity announcement (FOA) seeks to expand knowledge and increase the evidence base for palliative care (PC) in advanced rare diseases, including rare cancers, and to improve physical and psychosocial well-being and quality of life among seriously ill individuals and their family caregivers. Studies may consider changing needs that occur across time points and disease progression, as well as ways in which EOLPC and planning can adapt to meet these changing needs. Childhood cancers are not of interest for the purposes of this FOA.

NCI: Examine the unique physical and psychosocial issues related to EOLPC that may present among adults with advanced rare cancers (those with an incidence of fewer than 150 per million per year or approximately 40,000 cases or fewer) and their family/informal caregivers, including but not limited to psychological distress, prognostic uncertainty, social isolation, decisional regret, and decision-making in an emotional and ambiguous context.

Types of studies may include innovative methods or approaches such as qualitative, mixed methods, observational, quasi-experimental, and experimental with focus on individual- and family-centered outcomes. It is strongly encouraged that the investigative teams be interdisciplinary and include nurse scientists and early stage investigators. Investigators are also encouraged to consider using existing palliative care research networks, such as the Palliative Care Research Cooperative Group and other multisite data resources and research networks such as the National Cancer Institute Community Oncology Research Program, to carry out small, multi-site trials when appropriate.

Applications due February 16, 2017

  The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) (Deadline: 2/17/17)

The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)

The purpose of the NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to encourage and retain outstanding graduate students who have demonstrated potential and interest in pursuing careers as independent cancer researchers. The award will facilitate the transition of talented graduate students into successful cancer research postdoctoral appointments, and provide opportunities for career development activities relevant to their long-term career goals of becoming independent cancer researchers.

Applications due February 17, 2017

  Young Investigator Pilot Award (UCSF and ACSR Pilot Study – sponsored by NCI) (Deadline: 2/17/17)

Young Investigator Pilot Award (UCSF and ACSR Pilot Study – sponsored by NCI)

The AIDS and Cancer Specimen Resource (ACSR) is a resource for investigators working in the fields of HIV/AIDS, cancer, virology, immunology, pathology, epidemiology, tumor biology assay development, and many others. It is a biorepository for HIV-infected human biospecimens from a wide spectrum of HIV-related or associated diseases, including cancer, and from appropriate HIV-negative controls. The ACSR was established by the National Cancer Institute (NCI) in 1994 to acquire, store, and equitably distribute tumor tissues, biological fluids, and associated clinical information from patients with HIV-associated malignancies to the scientific research community-at-large.

The award is targeted toward junior investigators and faculty with innovative ideas for translational, clinical, or behavioral-epidemiological HIV-related research that utilizes ACSR's annotated biospecimens collected from HIV/AIDS patients and controls from both pre and post-HAART periods.

Awards are intended for pilot studies to show feasibility and/or to generate preliminary data that will support efforts to procure future funding of larger research projects.

ACSR holdings include samples and collections that could be used for pilot and feasibility studies to address areas of research that are of interest to the NCI (see full application for examples). Samples are from HIV-positive patients with and without malignancies, mainly non-Hodgkin lymphoma (NHL) and Kaposi's Sarcoma (KS) although small subsets of other cancers are available, as well as HIV-negative controls described in the application.

Applications due February 17, 2017

  Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33) (Deadline: 2/28/17)

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33)

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Applications due February 28, 2017

  Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33) (Deadline: 2/28/17)

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33)

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed.

This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Applications due February 28, 2017

  Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21) (Deadline: 2/28/17)

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21)

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology.

This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Applications due February 28, 2017

  Innovative Technologies for Cancer-Relevant Biospecimen Science (R21) (Deadline: 2/28/17)

Innovative Technologies for Cancer-Relevant Biospecimen Science (R21)

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Applications due February 28, 2017

  NCI Small Grants Program for Cancer Research (NCI Omnibus R03) (Deadline: 2/28/17)

NCI Small Grants Program for Cancer Research (NCI Omnibus R03)

This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

Applications due February 28, 2017

  Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01) (Deadline: 2/28/17)

Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of this FOA is on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response to treatment, as well as markers for cancer control and prevention. Research applications may support acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed for this FOA encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application.

This FOA is not intended to support early stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.

Applications due February 28, 2017

  START Mentored Translational Research Training Program (Extended deadline: 2/28/17)

START Mentored Translational Research Training Program

The overall goal of the START TL1 Program award is to increase the number of well-trained clinician-scientists who can lead the design and oversight of future clinical investigations critical to transforming the translational process so that new treatments and cures for disease can be delivered to patients faster. The deadline to submit a Letter of Intent has been extended to Dec. 21, and the application deadline has been extended to Feb. 28.

For this award cycle, applications are being accepted for:

  • Pre-doctoral awardees (MD/PhD, PhD, MD/MS) conducting clinical and translational research
  • Postdoctoral awardees (DMD, DC, DO, DVM, OD, DPM, ScD, EngD, AuD, DPT, DPH, DNSc, PharmD, ND (Doctor of Naturopathy), DSW, PsyD, a doctoral degree in nursing research or practice or an MD obtaining additional Masters training) conducting clinical and translational research

All TL1 awardees receive:

  • Stipend support awarded at the NIH allowed annual maximum:  For Pre-Doctoral Scholars (PhDs, MD/MSs, MD/PhDs) is 80% protected time with a stipend of $23,376 for one year.  For Post-Doctoral Scholars (MD Fellows) is 80% protected time with a one-year stipend, dollar amount varying depending on years of experience
  • Up to $5,700 for Pre-Doctoral Scholars and for Post-Doctoral Scholars up to $10,350 to defray the cost of the research program (including fringe benefits and travel to national meetings)
  • Access to the CTSI professional services and staff including biostatistics, subject recruitment, and human subjects approval; and access to a training curriculum in clinical and translational research methodology and specialized training seminars.
  • Up to 60% of tuition may be reimbursed

Applications due February 28, 2017

  Academic-Industrial Partnerships to Translate and Validate in vivo Cancer Imaging Systems (R01) (Deadline: 3/1/17)

Academic-Industrial Partnerships to Translate and Validate in vivo Cancer Imaging Systems (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging or spectroscopic technologies into methods or tools that address problems in cancer biology, risk of cancer development, diagnosis, treatment, and/or disease status.

A distinguishing feature of each application will be formation of an academic-industrial partnership, which is a strategic alliance of investigators in academic, industrial, and any other entities who work together as partners to identify and translate a technological solution or mitigation of a cancer-related problem.

The goals for proposed technologies are imaging applications in clinical trials, clinical research, non-clinical research, and/or patient care. Among other possibilities, they may include pre-clinical imaging investigations or investigations that combine patient specimens and pre-clinical methods, or optimizations of methods across different commercial platforms, sites, or time.

Applications due March 1, 2017

  Administrative Supplements for Research on Sexual and Gender Minority (SGM) Populations (Admin Supp) (Deadline: 3/1/17)

Administrative Supplements for Research on Sexual and Gender Minority (SGM) Populations (Admin Supp)

The NIH Office of the Director announces the availability of administrative supplements to expand existing research to focus on Sexual and Gender Minority (SGM) health. SGM populations include, but are not limited to, lesbian, gay, bisexual, and transgender people, and individuals with differences or disorders of sexual development (sometimes referred to as “intersex” or as specific diagnoses). This trans-NIH effort, which involves multiple Institutes, Centers and Offices from across NIH, is intended to encourage investigation in this underrepresented, but growing, field of research. To increase our collective understanding of the broad range of the health needs of SGM populations, the supplement will focus on areas of specific research interest, including, but not limited to: studies on increased disease risk; mental, behavioral and social health; approaches to personalized medicine; access to care; reproductive and sexual development; neurological and cognitive development; and resilience.

Applications due March 1, 2017

  Cancer Immunologic Data Commons (CIDC) (U24) (Deadline: 3/3/17)

Cancer Immunologic Data Commons (CIDC) (U24)

The purpose of this funding opportunity announcement (FOA) is to solicit applications for establishment of a Cancer Immunologic Data Commons (CIDC) to provide bioinformatics support as part of a Network for correlative studies in clinical trials involving cancer immunotherapy. The Network will encompass a single CIDC award (to be supported by this FOA) and up to three Cancer Immune Monitoring and Analysis Centers (CIMACs) (to be supported by a companion FOA, RFA-CA-17-005).

The goal of the CIMACs-CIDC Network is to enable systematic incorporation of biomarker studies in NCI-supported early clinical trials for immunotherapy. CIMACs will be responsible for comprehensive analyses of biospecimens from patients for biomarkers relevant to genomic, phenotypic, and functional aspects of responses to immunotherapy. CIDC will serve the bioinformatics needs of the Network, including collection, integration, access, and analysis of data generated from CIMACs. The CIDC will also contribute to the long-term goal of creating publically accessible Data Commons for cancer immune profiling as well as clinical data that will allow integrated analysis across trials and access by the larger immuno-oncology research community.

Specifically, the CIDC will be expected to:

  • Adopt or develop data collection standards and database modules for key assay platforms for tumor- and immune-profiling. This will be done in collaboration with CIMACs.
  • Establish database for collection and management of biomarker and associated clinical data generated from CIMACs.
  • Provide and maintain bioinformatics tools for data access and multi-dimensional analysis within and across trials in the CIMACs.
  • Facilitate regulated data sharing and access by outside investigators and research community, as appropriate and consistent with achieving the goals of the program.

The long term goal of the CIMACs-CIDC Network is to develop molecular signatures that define immune response categories to correlate with the clinical outcomes of immunotherapy in cancer. Collectively, the outcome of the Network research should lead to the identification of biomarkers with a translational potential for optimizing the therapeutic strategies for patients.

Applications are due March 3, 2017

  Cancer Immunologic Data Commons (CIDC) (U24) (Deadline: 3/3/17)

Cancer Immunologic Data Commons (CIDC) (U24)

This National Cancer Institute (NCI) funding opportunity announcement (FOA) solicits applications for multidisciplinary Cancer Immune Monitoring and Analysis Centers (CIMACs) that will serve as the main units of the Network for correlative studies in clinical trials involving immunotherapy. The Network will encompass two to three CIMACs (to be supported by this FOA) and a single Cancer Immunologic Data Commons (CIDC) (to be supported by the companion FOA, RFA-CA-17-006) forming a CIMACs-CIDC Network.

The Network is established to address the critical importance of biomarkers in management of cancer patients receiving immunotherapy. Specifically, each CIMAC will encompass a multidisciplinary group with basic, translational, clinical, and computational research expertise. CIMACs are expected to provide a wide range of state-of-the-art analyses for genomic, phenotypic and functional characterization of responses of patients in the NCI-sponsored early phase clinical trials using analytically-validated and standardized platforms. The Network activities will be facilitated by the CIDC in the following main areas: optimization of data collection methodologies suitable for immune-related biomarkers, data integration and building a biomarker database for the secondary use by the large immuno-oncology community.

The long term goal of the CIMACs-CIDC Network is to develop molecular signatures that define immune response categories to correlate with the clinical outcomes of immunotherapy in cancer. Collectively, the outcome of the Network research should lead to the identification of biomarkers with a translational potential for optimizing the therapeutic strategies for patients.

Applications due March 3, 2017

  Mechanisms of Cancer Drug Resistance and Sensitivity (U54) (Deadline: 3/3/17)

Mechanisms of Cancer Drug Resistance and Sensitivity (U54)

The goal of this Funding Opportunity Announcement (FOA) is to create a network of Drug Resistance and Sensitivity Centers (DRSCs) to develop innovative strategies to study mechanisms of tumor resistance or sensitivity to anticancer therapy. It is hoped that such studies will permit future efforts to identify and exploit these phenomena in clinical settings.

Each funded DRSC will become a member of the Drug Resistance and Sensitivity Network. Each DRSC may include multiple members and capabilities at the same or different institution that are necessary to fulfill the need for highly specialized multidisciplinary expertise. There may be multiple linked projects within each DSRC that will be under the overall authority of a Program Director/Principal Investigator (PD/PI). Applications involving several investigators from single or multiple institutions working together on a promising area of cancer resistance or sensitivity to drug therapy are encouraged.

The outputs from the DRSCs are expected to inform the development of novel strategies for precision medicine clinical trials (beyond the scope of this FOA) that can overcome drug resistance and sensitivity to anti-cancer agents.

Applications due March 3, 2017

  PDX Data Commons and Coordinating Center (PDCCC) for the PDX Development and Trial Centers Research Network (PDXNet) (U24) (Deadline: 3/3/17)

PDX Data Commons and Coordinating Center (PDCCC) for the PDX Development and Trial Centers Research Network (PDXNet) (U24)

The purpose of this funding opportunity announcement (FOA) is to establish a PDXNet Data Commons and Coordinating Center (PDCCC). PDCCC will interact with and coordinate with the PDX (Patient-Derived Xenograft) Development and Trial Centers Research Network (PDXNet) comprised of four PDX Development and Trial Centers (PDTCs, to be supported by companion FOA, RFA-CA-17-003) in a collaborative network.

The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale development and pre-clinical testing of targeted therapeutic agents in patient-derived models to advance the vision of cancer precision medicine. The goals for PDTCs include: development of new PDX models and methods for preclinical testing of single agents and drug combinations; and using the newly established models as well as other existing well-characterized PDX models for studies of drug responses. The PDCCC will serve as the coordinating and data analysis center of the PDXNet. It is expected that the outcomes of PDXNet research will be particularly important for the prioritization of combinations of agents in the portfolio of NCI Investigational New Drugs (NCI-IND agents), which are evaluated clinically in the NCI's Experimental Therapeutic Clinical Trials Network (ETCTN).

PDXNet will encompass four PDTCs (to be supported by a companion FOA, RFA-CA-17-003 ) and a single PDCCC (to be supported by this FOA). In addition, PDXNet will be supported by the NCI Patient-Derived Models Repository (PDMR) at the Frederick National Laboratory for Cancer Research (FNLCR). PDTCs and the PDCCC will be expected to collaborate with PDMR in several areas related to the goals of the program, including the development of optimized standardized procedures, and in sharing of PDX models.

Applications due March 3, 2017

  PDX Development and Trial Centers (PDTCs) (U54) (Deadline: 3/3/17)

PDX Development and Trial Centers (PDTCs) (U54)

This funding opportunity announcement (FOA) solicits applications for PDX (patient-derived xenografts) Development and Trial Centers (PDTCs) to serve as the laboratory research units of the PDX Development and Trial Centers Research Network (PDXNet). The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale development and pre-clinical testing of targeted therapeutic agents in patient-derived models to advance the vision of cancer precision medicine.

The main goals for PDTCs include:

  • Development of new PDX models and methods for preclinical testing of single agents and drug combinations; and
  • Conducting studies of response of PDX models to novel therapeutic strategies using the newly established models as well as other existing well-characterized PDX models.

It is expected that the outcomes of PDXNet research will be particularly important for the prioritization of combinations of agents in the portfolio of NCI Investigational New Drugs (NCI-IND agents), which are evaluated clinically in the NCI's Experimental Therapeutic Clinical Trials Network (ETCTN).

PDXNet will encompass four PDTCs (to be supported by this FOA) and a single PDX Data Commons and Coordinating Center (PDCCC) (to be supported by a companion FOA, RFA-CA-17-004). In addition, collaboration between PDXNet and the NCI Patient-Derived Models Repository (PDMR) at the Frederick National Laboratory for Cancer Research (FNLCR) will be required as part of this FOA. PDTCs will be expected to collaborate with PDMR in several areas related to the goals of the program, including the development of optimized standardized procedures, and in sharing of PDX models.

Applications due March 3, 2017

  Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies on the Tumor Microenvironment (U01) (Deadline: 3/7/17)

Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies on the Tumor Microenvironment (U01)

The purpose of this funding opportunity announcement (FOA) is to stimulate research in the area of PDAC microenvironment with the ultimate goal of understanding the interaction between tumors and the microenvironment. The plan is to design new immunotherapy and combination interventions that would accommodate and build on the distinct characteristics of this interaction. It is expected that the interventions will lead to improved responses in pre-clinical models and clinical evaluation either in NCI-based early phase networks (ETCTN), or by industry or cancer centers.

There is a need to better understand the role of inflammation in the genesis and progression of PDAC, the role of different effectors and suppressors of immune responses, the contribution of tumor stroma with the focus on its heterogeneity, and the function of tumor vasculature. Studying tumor-microenvironment interactions in PDAC should lead to the discoveries of vulnerabilities that could be exploited in the design of immunotherapies such as cancer vaccines, checkpoint inhibition, cellular therapies and their combination with other precision medicine interventions and radiation therapy.

Applications due March 7, 2017

  Canine Immunotherapy Trials and Correlative Studies (U01) (Deadline: 3/7/17)

Canine Immunotherapy Trials and Correlative Studies (U01)

This Funding Opportunity Announcement (FOA) will support canine clinical studies using immunotherapeutic agents and novel drug combinations (such as immune modulators, molecular targeted agents, chemotherapy, and/or radiation) together with laboratory correlative studies that seek to describe characterize and understand the cellular and molecular mechanisms that determine the anti-tumor response (or non-response) in dogs with spontaneous tumors. The FOA will support a network of laboratories and canine clinical trial sites. A companion funding opportunity (see U24 funding opportunity RFA-CA-17-002) will support a coordinating center that will aid in the development, standardization, and conduct of the clinical and laboratory studies as well as data management across the funded U01 sites.

Applications due March 7, 2017

  Coordinating Center for Canine Immunotherapy Trials and Correlative Studies (U24) (Deadline: 3/7/17)

Coordinating Center for Canine Immunotherapy Trials and Correlative Studies (U24)

This Funding Opportunity Announcement (FOA) will support a coordinating center for a network of cooperative agreements (see U01 FOA RFA-CA-17-001) that will conduct clinical trials in pet dogs with spontaneous tumors and perform laboratory correlative studies associated with the clinical trials.

This FOA will work with the NCI Comparative Oncology Program (COP) of the NCI's Center for Cancer Research as an integral component and will provide statistical support; assist with the development and standardization of clinical protocols and laboratory immune monitoring assays; assist with the implementation of clinical studies in immunotherapy and combination agents including accrual to the trials; manage clinical and correlative data from all U01 sites and their collaborators including immune-related adverse events; facilitate the sharing of agents, specimens, and data; and create an ad hoc steering committee of required expertise--both inside and outside the U01 network, including the PD/PIs of the U01s, representatives of the COP and the NCI Program Official--to ensure that the goals of the network are accomplished.

Applications due March 7, 2017

  Resource Center for the Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies (U24) (Deadline: 3/7/17)

Resource Center for the Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies (U24)

This funding opportunity announcement (FOA) invites applications to establish a Resource Center (RC) for the Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies on the Tumor Microenvironment (Consortium) that has the ultimate goal to design new immunotherapy and combination interventions in PDAC.

The RC will support the administrative coordination of the Consortium, create and support database(s) for data pertinent to the Consortium. It will secure centralized tissue banking for specimens submitted by the members of the Consortium and a virtual biospecimen database that would include all tissue resources of the Consortium. The RC will provide centralized bioinformatics and data analysis support, establish in vivo and in vitro model repositories and distribution units. Lastly, the RC will support meeting and communications coordination among members of Consortium, and form and maintain a Consortium website.

Applications due March 7, 2017

  NLM Administrative Supplements for Informationist Services in NIH-funded Research Projects (Admin Supp) (Deadline: 3/15/17)

NLM Administrative Supplements for Informationist Services in NIH-funded Research Projects (Admin Supp)

These administrative supplements provide funds to active awards of participating Institutes and Centers in order to enhance the storage, organization, management and use of digital research data through the involvement of informationists, also known as in-context information specialists. The purposes of this administrative supplement program are (1) to enhance collaborative, multi-disciplinary basic and clinical research by integrating an information specialist into the research team in order to improve the capture, storage, organization, management, integration, presentation and dissemination of digital biomedical research data; and (2) to assess the impact of the informationist’s participation.

Applications due March 15, 2017

  Tobacco Use and HIV in Low and Middle Income Countries (R01) (Deadline: 4/4/17)

Tobacco Use and HIV in Low and Middle Income Countries (R01)

The purpose of this funding opportunity announcement (FOA) is to encourage research focused on tobacco use and human immunodeficiency virus (HIV) infection in low and middle income countries (LMICs). In particular, applications are encouraged that focus on the development and evaluation of tobacco cessation interventions tailored to HIV positive populations, including those with co-morbidities such as tuberculosis (TB), in low-resource settings in LMICs. This FOA provides funding for research planning, intervention delivery, and follow-up activities.

Applications due April 4, 2017

  Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01) (Deadline: 4/11/17)

Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to encourage projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum.

The FOA is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control.

Applications due April 11, 2017

  Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R01) (Deadline: 6/5/17)

Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to promote research on interventions, based in healthcare settings, designed to reduce overscreening for breast, cervical, or colorectal cancers among average-risk older adults. While ongoing efforts to promote screening have been successful, there is growing concern that these tests may be overused, thereby subjecting adults to unnecessary risks. Overscreening older adults may be driven by factors at the individual, healthcare team, healthcare system and community organization levels. Therefore, research is needed both to understand the factors that drive overuse and to develop and test interventions that will reduce overuse in healthcare delivery systems.

Research supported by this FOA should propose to intervene at two or more levels, and should measure outcomes at two or more levels, while accounting for interactions that occur between levels. Research supported by this FOA should enhance knowledge and consequences of overscreening to improve the health, independence, and quality of life of older adults.

Applications due June 5, 2017

  Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R21) (Deadline: 6/16/17)

Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to promote research on interventions, based in healthcare settings, designed to reduce overscreening for breast, cervical, or colorectal cancers among average-risk older adults. While ongoing efforts to promote screening have been successful, there is growing concern that these tests may be overused, thereby subjecting adults to unnecessary risks. Overscreening older adults may be driven by factors at the individual, healthcare team, healthcare system and community organization levels. Therefore, research is needed both to understand the factors that drive overuse and to develop and test interventions that will reduce overuse in healthcare delivery systems.

Research supported by this FOA should propose to intervene at two or more levels, and should measure outcomes at two or more levels, while accounting for interactions that occur between levels. Research supported by this FOA should enhance knowledge and consequences of overscreening to improve the health, independence, and quality of life of older adults.

Applications due June 16, 2017

  KRAS Fellowship – Pancreatic Cancer Action Network | NCI, Frederick National Laboratory for Cancer Research (Deadline: 10/27/17)

KRAS Fellowship – Pancreatic Cancer Action Network | NCI, Frederick National Laboratory for Cancer Research

The KRAS Fellowship provides $100,000 in research funding over a two-year period. The grant term begins on July 1, 2017, and concludes on June 30, 2019. In addition to the research grant, Fellows are provided with $5,000 in travel support plus housing to visit FNLCR.

During the grant term, Fellows are given guest researcher status at FNLCR and are trained and granted access to onsite technology to support their funded research. They also receive support from the RAS Initiative team in planning experimental approaches for their funded project, mentorship from the RAS Initiative leadership and opportunities to participate in scientific lab meetings and workshops and to forge collaborations with other RAS researchers.

Fellows also attend the Pancreatic Cancer Action Network's Annual Scientific Meeting (scheduled for August 17-20, 2017, and dates to be determined in 2018 and 2019). This meeting brings together grant recipients and members of the organization’s Scientific and Medical Advisory Board for research feedback, knowledge exchange, mentorship and collaboration. Support for travel to the annual meeting is provided separate from the Fellowship grant.

Applications due October 27, 2017

  Tobacco Use and HIV in Low and Middle Income Countries (R21) (Deadline: 4/4/17)

Tobacco Use and HIV in Low and Middle Income Countries (R21)

The purpose of this funding opportunity announcement (FOA) is to encourage exploratory/developmental research focused on tobacco use and human immunodeficiency virus (HIV) infection in low and middle income countries (LMICs). In particular, applications are encouraged that focus on the development and evaluation of tobacco cessation interventions tailored to HIV positive populations, including those with co-morbidities such as tuberculosis (TB), in low-resource settings in LMICs. This FOA provides funding for research planning, intervention delivery, and follow-up activities.

Applications due April 4, 2017

National Institutes of Health (NIH)

Open AllClose All
  Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42) (Deadline: 2/22/17)

Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42)

This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications that propose to develop a product, process or service for commercialization with the aim of reducing disparities in healthcare access and health outcomes in one or more NIH-defined health disparity population group(s). Appropriate technologies should be effective, affordable, culturally acceptable, and deliverable to racial/ethnic minorities, low-income and rural populations.

Applications due February 22, 2017

  Time-Sensitive Obesity Policy and Program Evaluation (R01)

Time-Sensitive Obesity Policy and Program Evaluation (R01)

This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding.

All applications to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications in response to this time-sensitive FOA are not eligible for resubmission. It is intended that eligible applications selected for funding will be awarded within four months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.

Applications due on a continuous basis (once per month)

Department of Defense (DOD)

Foundations & Organizations

Open AllClose All
  American Urological Association (AUA) Urology Care Foundation (Deadline: 1/15/17)

American Urological Association (AUA) Urology Care Foundation

These awards provide motivated and exceptional urology residents with mentored training to prepare them for careers that include urologic research. Residents conduct research under the direction of an accomplished mentor. Conducting urologic research is an exciting and vital activity for medical professionals. Research training during urology residency provides residents with exposure to this potential career path and experience to enable them to continue their development towards becoming independent investigators. Importantly, residency research training has the potential to address the critical and increasing shortfall of urology surgeon-scientists and to play a key role in departmental and institutional contributions to science and to improving patients' lives through research.

Applications due January 15, 2017

  Moore Inventor Fellows - The Gordon and Betty Moore Foundation (Institutional Deadline: 1/17/17 - Foundation Deadline: 3/1/17)

Moore Inventor Fellows - The Gordon and Betty Moore Foundation (Institution) (Foundation)

In 1965, Gordon Moore predicted the doubling of components on an integrated circuit every 18 months. From careful observation of an emerging trend, Moore extrapolated that computing would dramatically increase in power, and decrease in relative cost, at an exponential pace. This observation helped fuel the technological advancement and acceleration we have seen in the past 50 years.

With the creation of the Moore Inventor Fellows, the foundation hopes to enable breakthroughs that accelerate progress over the next 50 years. This new fellowship program recognizes early-career innovators at U.S. universities with a high potential to accelerate progress in scientific research, environmental conservation and patient care.

Each fellow will receive a total of $825,000 over three years to drive their invention forward, including $50,000 per year from their home institution as commitment to these outstanding individuals. Beginning with these five fellows in 2016, the foundation will invest nearly $34 million during the next ten years to support 50 Moore Inventor Fellows.

Institutional Applications due January 17, 2017

Foundation Applications due March 1, 2017

  St. Baldrick’s Foundation (Pre-application deadline: 1/18/17)

St. Baldrick’s Foundation

Five funding opportunities (1. Research Grants, 2. Supportive Care Research Grants, 3. Baldrick’s Fellowships, 4. Consortium Research Grants, and 5. Scholar Awards) are currently available. Due to the limitation of one or two applications per institution for each of the available opportunities, pediatric oncology leaders from MCW will select the final candidates to submit full proposals to St. Baldrick’s. If interested in applying, please see instructions below:

Pre-Application Process

Please submit the following materials by email to Terri Misorski, Grants Operations Coordinator, (tmisorsk@mcw.edu), by noon (12:00 p.m. CST) on Wednesday, January 18, 2017:

  1. Letter of Nomination from senior or supervising faculty member
  2. Brief description from the nominee of his/her proposed research project (one-page maximum)
  3. Nominee's current NIH biosketch

Deadlines

Pre-application materials are due to Terri Misorski, (tmisorsk@mcw.edu), by noon (12:00 p.m. CST) on Wednesday, January 18, 2017.

  • Applicants will be notified of the selection no later than Wednesday, January 25, 2017
  • Letters of Intent for selected applicants are due to St. Baldrick’s by January 31, 2017
  • Full application for the selected applications will be due to St. Baldrick’s by 5:00 p.m. EST on March 31, 2017

If you have any questions regarding this opportunity or the pre-application process, please contact Terri Misorski directly.

  Caroline Craig Augustyn and Damian Augustyn Award in Digestive Cancer | American Gastroenterological Association (AGA) – AGA Research Foundation (Deadline: 1/20/17)

Caroline Craig Augustyn and Damian Augustyn Award in Digestive Cancer | American Gastroenterological Association (AGA) – AGA Research Foundation

This award is for a young investigator, instructor, research associate or equivalent who currently holds a federal or non-federal career development award devoted to conducting research related to digestive cancer. The objective is to support young investigators conducting research relevant to the pathogenesis, prevention, diagnosis, or treatment of digestive cancer. The award is intended to supplement existing career development funding

Applications due January 20, 2017

  SFA Research Grants | Sarcoma Foundation of America (SFA) (Deadline: 1/31/17)

SFA Research Grants | Sarcoma Foundation of America (SFA)

The SFA has developed a program to provide grants to investigators interested in translational science Sarcoma research. Funding is available in support of research on the etiology, molecular biology, pathogenesis, diagnosis, and treatment of human Sarcomas.

In accordance with the mission of the Foundation, research involving the development of novel agents against Sarcoma, or research that could potentially lead to the development of novel agents against Sarcoma, is eligible for this funding. The SFA strongly prefers and will give special consideration to applications that focus on the following areas:

  • Omic characterization of sarcomas and definition of novel targets
  • Omic patterns of sensitivity and resistance to existing agents
  • Systematic therapy combinations
  • Immunotherapy

In compliance with IRS instructions, grants cannot fund clinical trials, but all other areas of research can be considered for funding.

Applications due January 31, 2017

  The National Pancreas Foundation (Deadline: 1/31/17)

The National Pancreas Foundation

The National Pancreas Foundation (NPF) is a private, non-profit organization established to support the funding of research related to pancreatic diseases. It also provides support for the men, women, and children who are suffering from diseases of the pancreas. The research must be in the field of pancreatic diseases. Studies intended to advance knowledge in the areas of pancreatic carcinoma, and all forms of pancreatitis would be the closest to the areas of interest of the NPF. Studies more closely related to diabetes will not be accepted.

Applications due January 31, 2017

  Elsa U. Pardee Foundation (Deadline: 2/1/17)

Elsa U. Pardee Foundation

The Elsa U. Pardee Foundation funds investigators proposing research directed toward identifying new treatments or cures for cancer. The foundation particularly encourages grant applications for a one-year period which will allow establishment of capabilities of new cancer researchers, or new cancer approaches by established cancer researchers. It is anticipated that this early stage funding by the foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified.

Applications due February 1, 2017

  Lasker Awards | Lasker Foundation, Albert and Mary (Deadline: 2/1/17)

Lasker Awards (Lasker Foundation, Albert and Mary)

The Lasker Awards are among the most respected science prizes in the world. Since 1945, the Awards Program has recognized the contributions of scientists, physicians, and public servants who have made major advances in the understanding, diagnosis, treatment, cure, and prevention of human disease.

The Albert Lasker Basic Medical Research Award honors scientists whose fundamental investigations have provided techniques, information, or concepts contributing to the elimination of major causes of disability and death.

The Lasker~DeBakey Clinical Medical Research Award honors investigators whose contributions have improved the clinical treatment of patients.

The Lasker~Koshland Special Achievement Award in Medical Science honors scientists whose contributions to research are of unique magnitude and have immeasurable influence on the course of science, health, or medicine, and whose professional careers have engendered within the biomedical community the deepest feelings of awe and respect.

The Lasker~Bloomberg Public Service Award honors men and women who have helped make possible the federal legislation and funding that supports research, and who have created public communication, public health, and advocacy programs of major importance.

Applications due February 1, 2017

  LIMITED: Damon Runyon Clinical Investigator Award (Damon Runyon Cancer Research Foundation) (Deadline: 2/1/17)

LIMITED: Damon Runyon Clinical Investigator Award (Damon Runyon Cancer Research Foundation)

The Damon Runyon Clinical Investigator Award supports independent young physician-scientists conducting disease-oriented research that demonstrates a high level of innovation and creativity. The goal is to support the best young physician-scientists doing work aimed at improving the practice of cancer medicine. Patient-oriented research, epidemiologic and behavioral studies, or outcomes research and health services research which is focused on cancer.

Applications due February 1, 2017

  American-Italian Cancer Foundation (AICF) (Deadline: 2/28/17)

American-Italian Cancer Foundation (AICF)

AICF is proud to sponsor the work of bright young scientists who perform groundbreaking research in the fields of cancer biology and treatment in competitive labs across the United States.

The Program provides financial support for the post-doctoral research of bright young scientists who pursue research and advanced training in collaboration with mentors at major cancer centers in the United States.

Post-doctoral research fellowships are a critical component in advancing cancer research, as they support talented young scientists with innovative project ideas at a time in their careers when funding from other sources is less certain. AICF's Program differs from most other U.S.-based research fellowship programs in that it focuses on providing opportunities for Italian researchers to train and conduct research at the major cancer centers in the United States.

Eligible applications for an AICF Fellowship include proposals for basic or translational cancer research, as well as clinical research.

Applications due February 28, 2017

  Career Development Award (CDA) - Melanoma Research Foundation (MRF) (Deadline: 3/1/17)

Career Development Award (CDA) - Melanoma Research Foundation (MRF)

MRF is committed to advancing research across the spectrum of melanoma - from prevention through diagnosis, staging and treatment. The MRF proactively partners with the NCI, Congress, the Department of Defense and other foundations to develop and collaborate on a broad agenda for melanoma research that takes full advantage of all opportunities, while also sharing challenges.

All CDA Awards must address one of the Specific Topic Proposals (STPs) identified below.

SPECIFIC TOPIC PROPOSALS (STPs):

The identification of scientific topics that address unmet clinical needs in melanoma research were identified through a series of meetings of multidisciplinary experts from the MRF's Scientific Advisory Committee and Breakthrough Consortium Steering Committee. The following categories are the identified unmet needs in melanoma research selected as STPs for 2017:

  • Prevention: Development of models and biomarkers
  • Identifying mechanisms and respective therapeutic strategies in less common molecular subsets of melanoma
  • Metastases: Dormancy and metastatic progression
  • CNS Metastases: Development of markers of risk and rational therapeutic approaches
  • Response to treatment: Mechanisms and respective biomarkers for predicting response and for monitoring therapeutic response
  • Resistance: Intrinsic/Innate/Primary resistance to immunotherapies in melanoma

Applicants must clearly indicate which of the categories - if any - is being addressed in their application. In all cases, the scientific merit is the most important factor underlying the selection for funding.

The use of relevant genetic models and/or human derived tumor samples is highly encouraged, but not required.

Proposed research must comply with all applicable National Institutes of Health (NIH) animal and human welfare guidelines.

Applications due March 1, 2017

  Established Investigator Awards (EIA) - Melanoma Research Foundation (MRF) (Deadline: 3/1/17)

Established Investigator Awards (EIA) - Melanoma Research Foundation (MRF)

The Melanoma Research Foundation (MRF) is committed to advancing research across the spectrum of melanoma – from prevention through diagnosis, staging and treatment. The MRF proactively partners with the NCI, Congress, the Department of Defense and other foundations to develop and collaborate on a broad agenda for melanoma research that takes full advantage of all opportunities, while also sharing challenges. The EIAs provide funding of up to $100,000 per year for two years to established melanoma researchers, or senior researchers working in closely related fields who wish to move into melanoma research.

Applications are due March 1, 2017

  Medical Student Awards - Melanoma Research Foundation (MRF) (Deadline: 3/1/17)

Medical Student Awards - Melanoma Research Foundation (MRF)

The Melanoma Research Foundation (MRF) is committed to advancing research across the spectrum of melanoma – from prevention through diagnosis, staging and treatment. The MRF proactively partners with the NCI, Congress, the Department of Defense and other foundations to develop and collaborate on a broad agenda for melanoma research that takes full advantage of all opportunities, while also sharing challenges. The MRF is committed to introducing students early in their career to the clinical or research opportunities under the mentorship of an investigator engaged in melanoma research. These awards provide opportunities and funding for medical students to engage in short clinical or laboratory-based research projects focused on better understanding the biology and treatment of melanoma. As such, medical students are encouraged to submit applications for the $3,000 award for 1 year of research.

Applications due March 1, 2017

  Translational Research Program | Leukemia and Lymphoma, Familial Platelet Disease (FPD) / RUNX1 and Myeloma (Deadline: 3/1/17)

Translational Research Program | Leukemia and Lymphoma, Familial Platelet Disease (FPD) / RUNX1 and Myeloma

The Leukemia & Lymphoma Society (LLS) and the Babich Family Foundation/RUNX1 Research Program are partnering to launch a competitive grant to advance new therapies for, and greater understanding of familial platelet disorders associated with RUNX1 mutations that lead to acute myelogenous leukemia. The program is focused on addressing translational research with a total of $1.8 million; 3 grants will be awarded up to $600,000 each. The applications will be evaluated by a dedicated team of experts and ranked separately from our normal Leukemia and Lymphoma TRP applications.

Applications are sought proposing novel approaches to the prevention, diagnosis or treatment of hematological malignancies and related pre-malignant conditions. Proposals should be based on molecular, cellular or integrated systems findings and be conceptually innovative. The application should have a clear plan for the clinical translation of the studies proposed and the results expected. This feature will be an important consideration of the review process.

This program is intended to provide support over an initial three-year period. Two additional years may be available through the competitive, peer-reviewed TRP Renewal process to solidify progress made in the initial award and further support a clinical trial. To be considered for a TRP renewal award, a clinical protocol for a Phase I or Phase II clinical trial based on the initial Translational Research Program grant must be submitted to the institution's IRB for approval and the work must be a direct result of the funded TRP award.

Applications due March 1, 2017

  Distinguished Scientist Award (DSA) | The Sontag Foundation (Deadline: 3/15/17)

Distinguished Scientist Award (DSA) | The Sontag Foundation

This award seeks to provide career and research support to early career scientists who demonstrate outstanding promise for making scientific and medical breakthroughs in the field of brain cancer research.

Recipients of the award are inspired individuals with projects that show potential to generate new knowledge relating to causes, cure or treatment of primary brain tumors/brain cancer. Applicant's career track and proposed research should demonstrate potential to generate new knowledge relating to causes, cure or treatment of primary brain tumors/brain cancer.

Applications due March 15, 2017

  Elsa U. Pardee Foundation (Deadline: 4/30/17)

Elsa U. Pardee Foundation

The Elsa U. Pardee Foundation funds investigators proposing research directed toward identifying new treatments or cures for cancer. The foundation particularly encourages grant applications for a one-year period which will allow establishment of capabilities of new cancer researchers, or new cancer approaches by established cancer researchers. It is anticipated that this early stage funding by the foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified.

Applications due April 30, 2017

  LUNGevity Career Development Awards for Translational Research (LUNGevity Foundation) (Deadline: 5/5/17 - by invitation only)

LUNGevity Career Development Awards for Translational Research (LUNGevity Foundation)

LUNGevity Foundation is a 501(c)(3) philanthropy specifically focused on funding research for the early detection and successful treatment of lung cancer. LUNGevity's mission is to improve mortality rates of lung cancer patients through the development of protocols and tools for early detection of lung cancer, early intervention in the disease progression, and targeted therapeutics, including immuno-oncology. LUNGevity focuses on translational science.

LUNGevity's Career Development Awards for Translational Research program was created with one goal: to support future research leaders who will keep the field of lung cancer research vibrant with new ideas. Research projects are restricted to translational lung cancer research, and the applicant must demonstrate the translational relevance of the research proposed. The CDAs are mentored awards; a mentoring plan will be part of the required submission.

High-risk, high-return proposals will receive equal consideration. Translational research includes epidemiology studies, and LUNGevity especially encourages clinical correlative studies. Proposed projects must make use of human biopsies or samples. In vivo primary tumor explants meet these criteria, but xenografts from established cell lines do not. Translational research includes epidemiologic, clinical/correlative, or thoracic surgical research. The use of existing resources is encouraged, including libraries of compounds or probes, tissue or bio-specimen repositories, and other existing sets of tissue, blood, or images. It is strongly encouraged that those applying have direct and immediate access to the bio-specimens necessary to complete their research.

Applications due May 5, 2017 (by invitation only)

  St Baldrick’s Foundation (SBF) (Deadline: 8/31/17)

St Baldrick’s Foundation (SBF)

These grants are not for a specific research project, but rather for resources to allow more research to be done. They support institutions with the potential for more participation in childhood cancer clinical trials, but which currently lack necessary resources (primarily support for Clinical Research Associates). Infrastructure grants are designed to provide an infusion of funds to enable an institution to acquire the personnel (i.e., a clinical research associate) or resources it needs to reach its potential in broader clinical trial participation. The applicant should indicate how ongoing personnel costs will be funded in future years.

Applications due August 31, 2017

  Graduate Training in Disparities Research (GTDR) | Komen for the Cure, Susan G. (Deadline: TBA)

Graduate Training in Disparities Research (GTDR) | Komen for the Cure, Susan G.

Graduate Training in Disparities Research (GTDR) Grants are intended to establish and/or to sustain a training program for graduate students who are seeking careers dedicated to understanding and eliminating disparities in breast cancer outcomes across population groups.

By providing funding to outstanding training programs, Komen seeks to ensure that a diverse pool of highly trained scientists will emerge as the next generation of leaders in the field of breast cancer research focused on disparities in breast cancer outcomes.

The research training program should be designed to meet the following goals:

  • Attract graduate students, specifically those from populations affected by disparities in breast cancer outcomes, into research careers.
     
  • Empower these students with the skills and knowledge necessary to effectively explore the causes of differential breast cancer outcomes and develop interventions to reduce and eliminate such disparities.

Deadline TBA

  Distinguished Scholars | Lustgarten Foundation

Distinguished Scholars | Lustgarten Foundation

The Distinguished Scholars program supports world-class scientists, who are at the top in their field, and are at the forefront of today's most exciting breakthroughs in pancreatic cancer research. Selected by The Lustgarten Foundation's Scientific Advisory Board (SAB), each grantee will receive $5 million in funding over the next five years, enabling these scientists to purse high-risk high-reward science, dedicate more of their time and focus to pancreatic cancer research, and accelerate a path to a cure.

The Distinguished Scholar Award is given on a discretionary basis and is not part of the annual grant program.

  Komen Southeast Wisconsin's Small Grant Program

Komen Southeast Wisconsin's Small Grant Program

Any non-profit organization in the Komen Southeast Wisconsin service area can apply for up to $5,000 for a small pilot or capacity-building breast health program grant. These grants are for organizations interested in beginning a new program or testing new ideas that will increase the innovative capacity and effectiveness of breast health programs that serve low income and uninsured women.

Small Grants are available in two categories:

  1. Education/Outreach Grants will support the development of breast cancer programs or projects.
     
  2. Capacity Building/Technical Assistance Grants will provide funding to increase the efficiency and effectiveness of an organization's ability to provide services by redesigning processes, implementing new practices, or developing collaborations or partnerships.

Applications due on a continuous basis throughout funding cycle

  Pediatric Low Grade Astrocytomas Foundation (PLGA)(Applications continuous)

Pediatric Low Grade Astrocytomas Foundation (PLGA)

The number one priority of A Kids' Brain Tumor Cure Foundation is to act as a catalyst for researchers world-wide to turn their attention to the area of pediatric low grade glioma brain tumor research and to award research grants for the most promising programs and studies. The hope is that this research will lead to a better understanding of the causes of PLGA as well as the discovery of more effective treatments and a cure for the most common forms of children's brain tumors.

Proposals related to basic and translational* projects that can advance understanding of the underlying biology of the development and treatment of PLGA tumors will be considered.

*NIH definition of translational research: the process of applying ideas, insights, and discoveries generated through basic scientific inquiry to the treatment or prevention of human disease.

Applications continuous

  SWOG Trial Support (STrS) – The Hope Foundation (Applications continuous)

SWOG Trial Support (STrS) – The Hope Foundation

SWOG's mission is to improve the practice of cancer medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors, primarily through design and conduct of clinical trials. SWOG is a National Cancer Institute-supported network of more than 5,000 cancer researchers at more than 650 institutions in the U.S., Canada, and beyond. Additional educational and cancer research support is provided by SWOG's non-profit, philanthropic partner, The Hope Foundation.

STrS is a peer-reviewed program administered by The Hope Foundation in conjunction with SWOG. STrS is designed to support trial components that need supplemental funding during patient enrollment in a SWOG study. Qualifying components may include things that are outside of the SWOG-supported norm, such as atypical requests for tissue and/or data, or provision of materials to trial sites.

Applications continuous

Pancreatic Cancer Action Network

Institutional

Other

Open AllClose All
  Clinical Investigator Award | Society of Surgical Oncology (SSO) (Deadline: 1/17/17)

Clinical Investigator Award | Society of Surgical Oncology (SSO)

The purpose of this award is to promote patient-oriented research conducted by surgical oncologists in clinical and translational science. The Foundation requests a proposal in which the applicant plays a central role in the conduct of a specific clinical research project. This might include for example a leadership role in a clinical trial, in a prospective cancer outcomes study, or a translational research project related to a prospective clinical trial. The clinical research focus must be hypothesis-driven and must have a direct patient-oriented focus. Clinical trials may be investigator-initiated, industry-driven or organized by a cooperative group.

Of note, this award is not intended to serve as a career development award for new investigators seeking to initiate their research careers.

Applications due January 17, 2017

  Childs Memorial Fund for Medical Research | Jane Coffin (JCC Fund) (Deadline: 2/1/17)

Childs Memorial Fund for Medical Research | Jane Coffin (JCC Fund)

The Fund was established in 1937 for the purpose of supporting research into the causes and treatment of cancer. The Fund has taken a broad approach to the study of cell growth and development, emphasizing the study of the basic biology and chemistry of the underlying processes. The Fund has increasingly focused its resources on the funding of postdoctoral Fellowships, supporting Fellows selected by its Board of Scientific Advisers from among the best young scientists at what is often a critical stage in their careers.

Applications due February 1, 2017

  Clinic and Laboratory Integration Program (CLIP) | Cancer Research Institute (Deadline: 2/1/17)

Clinic and Laboratory Integration Program (CLIP) | Cancer Research Institute

CLIP Grants provide funding for qualified scientists who are working to explore clinically relevant questions aimed at improving the effectiveness of cancer immunotherapies. The grant will support basic, pre-clinical, and translational research, which will provide information that can be directly applied to optimizing cancer immunotherapy in the clinic.

Letter of Intent due November 1, 2016

Applications due February 1, 2017

  Pancreatic Cancer Action Network Precision Medicine Targeted Grant (Deadline: 2/15/17)

Pancreatic Cancer Action Network Precision Medicine Targeted Grant

This Request for Applications is to solicit Precision Medicine Targeted Grant applications to provide funding for projects that can be incorporated directly into the Pancreatic Cancer Action Network’s Precision Promise initiative at the end of the funding period. Applications for any amount of money up to $1 million total (direct plus a maximum of 20 percent indirect costs) for a time period up to two years are solicited. Applications from academic institutions or for-profit biotechnology or pharmaceutical firms are accepted.

Applications due February 15, 2017

  Bladder Cancer Advocacy Network (BCAN) (Deadline: 3/1/17)

Bladder Cancer Advocacy Network (BCAN)

This Award is intended to support the development of outstanding research scientists and clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of bladder cancer. Investigators may be working in basic, translational, clinical, epidemiologic, bioengineering or any other field, but must be working in a research environment capable of supporting transformational bladder cancer research. The project must be bladder cancer specific (including upper tract urothelial carcinoma).

Applications due March 1, 2017

  Research Grant Program: A-T Post Doctoral Fellowship Award (Deadline: 3/1/17)

Research Grant Program: A-T Postdoctoral Fellowship Award

Ataxia-telangiectasia, or A-T, is a rare genetic disease that attacks children, causing progressive loss of muscle control, immune system problems, and a high rate of cancer. A-T affects a large variety of systems in the body, causing symptoms that affect health and daily living.

The A-T Children's Project strives to assist respected scientists around the world in developing a clearer understanding of A-T. The A-T Children's Project is determined to find a timely cure, or life-improving treatments, for this serious disease. Postdoctoral fellowships are available.

The A-T Children's Project provides competitive grant awards for basic and translational research grants related to A-T.

The A-T Children's Project is currently focusing its funding efforts on proposals that apply innovative and novel strategies for suggesting, developing and evaluating specific disease-modifying and symptomatic interventions with an emphasis on:

  • translational (bench to bedside) research
  • clinical studies

Applications due March 1, 2017

  Specialized Center of Research Program | Leukemia & Lymphoma Society (Deadline: 3/1/17)

Specialized Center of Research Program | Leukemia & Lymphoma Society

LLS's Specialized Center of Research (SCOR) grant program is intended to bring together established investigators from one or several institutions to develop a focused research program, foster new interactions and cooperation, and enhance interdisciplinary research among the participants. The overall goal of this mechanism is to enhance the development of innovative strategies for the treatment, diagnosis or prevention of hematological malignancies. Strategies that move discoveries from the bench to the clinic are of high importance as are integrated translational projects.

Applications due March 1, 2017

  Innovation Grant: Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF) (Deadline: 3/6/17)

Innovation Grant: Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF)

The overall objectives of this grant are to advance cell and gene therapy into the causes, treatment and prevention of all types of cancer by promoting development of novel and innovative studies by young investigators. The emphasis of this initiative is to promote basic and pre-clinical research approaches utilizing cells and genes as medicine. ACGT will direct its grants into areas of cell and gene therapy research that have demonstrated great promise.

The seven main areas of research ACGT will support are:

  1. Tumor-Specific Replicating Viruses and Bacteria
  2. Anti-angiogenesis
  3. Immune-modulatory Therapy and Cancer Vaccines
  4. Oncogene/Suppressor Oncogene/Apoptosis Directed Therapy 9
  5. Tumor Targeting and Vector Development
  6. Cancer Stem Cell Directed Therapy
  7. Other Gene/Cell based Therapies

Applications due March 6, 2017

  2017 ASPIRE Oncology/Hematology Research Awards – Advanced Breast Cancer (Deadline: 3/31/17)

2017 ASPIRE Oncology/Hematology Research Awards – Advanced Breast Cancer

The mission of the ASPIRE Awards program is to support clinical research involving select Pfizer compounds in the fields of Oncology and Hematology through a competitive grants program. This program is to support continuous medical research to maximize the available therapies by improving medical knowledge and clinical management of the disease. Pfizer invites investigators to apply for the 2017 ASPIRE Oncology & Hematology Research Awards through submission of innovative clinical research proposals designed to accomplish the mission of advancing knowledge of select Pfizer compounds in the treatment and disease management of breast cancer. Pfizer is interested in supporting 3-5 clinical studies of palbociclib in advanced breast cancer, focusing in the following areas:

  • In hormone receptor positive (HR+) advanced breast cancer, optimal clinical management and/or nursing management that addresses or improves patient compliance and convenience and/or patient reported outcomes, such as management of non-hematological side effects, bone only disease, and other supportive measures, during palbociclib treatment. Proposals may be a clinical trial, a nursing focused study, or a non-interventional retrospective study under this category
  • In HR+ advanced breast cancer, safety and efficacy profile of palbociclib in combination with hormone therapy, chemotherapy, or other modality in particular patient populations, such as patients with substantial tumor burden, with disease in liver, or with co-morbidities. Safety monitoring should be a significant part of the proposal
  • In HR+ advanced breast cancer, clinical exploration of the role of palbociclib based combination in post palbociclib/hormone therapy in appropriate MBC patients
  • In HER2+ advanced breast cancer patients, safety and efficacy profile of palbociclib in combination with T-DM1 in patients who previously received trastuzumab and a taxane

In addition, the following would be of interest: incorporation of a correlative/biomarker component into the proposed clinical study using paired biopsy samples (e.g. pre- and post- treatment), liquid biopsy, or PK/PD biomarkers to explore potential mechanism of action, as well as sensitivity and resistance mechanisms.

Applications due March 31, 2017

  2017 ASPIRE Oncology/Hematology Research Awards – Advanced Breast Cancer (Deadline: 3/31/17)

2017 ASPIRE Oncology/Hematology Research Awards – Advanced Breast Cancer

The mission of the ASPIRE Awards program is to support clinical research involving select Pfizer compounds in the fields of Oncology and Hematology through a competitive grants program. This program is to support continuous medical research to maximize the available therapies by improving medical knowledge and clinical management of the disease. Pfizer invites investigators to apply for the 2017 ASPIRE Oncology & Hematology Research Awards through submission of innovative clinical research proposals designed to accomplish the mission of advancing knowledge of select Pfizer compounds in the treatment and disease management of acute leukemia. Pfizer is interested in supporting 1-2 studies of each of the following compounds in acute leukemia, focusing in the following areas:

Inotuzumab Ozogamicin

  • Defining the optimal sequencing and dosing of inotuzumab with other treatment options
  • Evaluating the impact of inotuzumab on immune cell functions and identifying immune-related biomarkers
  • Clarifying the role of MRD in the treatment relapsed and refractory Acute Lymphoblastic Leukemia
  • Identifying the early onset biomarkers for liver toxicities and VOD/SOS in inotuzumab-treated patients and exploring preventive, monitoring, and therapeutic measures
  • Exploring the impact of cytogenetic abnormalities or other genomic factors to inotuzumab clinical outcome

Gemtuzumab Ozogamicin

  • Evaluating gemtuzumab fractionated dosing regimen in combination or in sequence with novel agents (eg, targeted agents or immunotherapies) and/or HSCT in previously untreated patients with AML and identification of biomarkers guiding the choice of combination therapies and treatment settings
  • Evaluating gemtuzumab fractionated dosing regimen in combination with low intensity regimens (eg. decitabine, 5-azacitadine) in previously untreated patients with AML
  • Evaluating and optimizing gemtuzumab fractionated dosing regimen as monotherapy or in combination with other agents in patients with relapse AML
  • Evaluating gemtuzumab fractionated dosing regimen in combination with conventional or novel agents in patients with APL
  • Scientific studies involving gemtuzumab focused on the following topics: impact of genetic polymorphism in CD33 on behavior and clinical outcomes; modulation of CD33 by therapy and impact on dosing schedule; biomarkers predicting response/non-response; understanding mechanism of resistance; contemporary approaches to MRD monitoring and correlation with response/duration of remission

Palbociclib

  • Evaluating safety and efficacy profile of palbociclib containing regimen in acute leukemia adult patients or pediatric patients (who are able to swallow pill)

Applications due March 31, 2017

  PSC Partners Seeking a Cure (Deadline: 4/1/17)

PSC Partners Seeking a Cure

PSC Partners Seeking a Cure is a 501(c)(3) nonprofit organization whose mission is to provide education and support to PSC patients, families and caregivers and to raise funds to research causes, treatments and cures for primary sclerosing cholangitis. PSC Partners offers grants to conduct research that addresses an important and novel, basic or clinical research question related to PSC and closely associated diseases (such as inflammatory bowel diseases (IBD), ulcerative colitis (UC) or Crohn's disease) as they relate to PSC. The applicant must be at an academic institution with an interest in pursuing PSC as an indication for treatment. The purpose is to encourage investigators to conduct research in promising new areas with the goal that data generated will lead to federal (NIH) funding.

PSC Partners Seeking a Cure is particularly interested in funding research projects that have the potential to discover a cure for this disease, and/or identify novel therapies that may significantly delay time to liver transplantation, prevent disease recurrence following liver transplantation, and/or improve the quality of life of those with PSC. PSC Partners understands that much fundamental research is necessary to discover the environmental factors that may trigger this disease in genetically susceptible individuals, and therefore we would like to encourage research proposals aimed at identifying the gene-environment interactions contributing to disease initiation and progression. PSC Partners recognizes that studies with animal models may be appropriate to address these fundamental questions. We are interested in funding research that explores PSC-related diseases (IBD, UC, and Crohn's disease) in ways that they impact, enable, or perhaps cause PSC. PSC Partners encourages research that will be complementary to the goals and objectives of the International PSC Study Group, including investigation of the functional roles of genes associated with susceptibility to and severity of PSC. Other priority areas for research include the mechanisms of PSC pathogenesis and colorectal and cholangiocarcinoma carcinogenesis as well as strategies for prevention. Applications focused on assessing and improving the quality of life of PSC patients are also encouraged. Proposals that have little relevance to PSC will not be considered for funding. We strongly encourage interdisciplinary collaborations and the sharing of resources as a means of accelerating progress in PSC research. If the proposal includes a specific plan for sharing of results and resources (such as DNA), this will result in a more favorable review. Applications addressing PSC in children are strongly encouraged.

Applications due April 1, 2017

  Pilot and Exploratory Projects in Palliative Care of Cancer Patients and Their Families (ACS) (Deadline: 4/3/17)

Pilot and Exploratory Projects in Palliative Care of Cancer Patients and Their Families (ACS)

Pilot data are typically needed before funding agencies (e.g., NIH, VA or the American Cancer Society) will consider funding a research project. In an effort to support clinician investigators conducting patient-oriented research in palliative care, the Society, in parallel with the National Palliative Care Research Center (NPCRC), is soliciting applications for pilot/exploratory research grants in palliative care of cancer patients and their families. These grants will generate the pilot data necessary to maximize an investigator's chances of competing successfully for larger grants.

This RFA provides funding for investigators performing pilot and exploratory research studies whose purpose is to test interventions, develop research methodologies, and explore novel areas of research in palliative care of cancer patients and their families. A condition of funding is a clearly defined plan as to how the investigator will use the results of the project to develop larger, extramurally funded research projects.

This RFA is limited to applications that focus on palliative care research projects for seriously ill cancer patients and their families in three specific areas:

  1. Exploring the relationship of pain and other distressing symptoms on quality and quantity of life, independence, function, and disability and developing interventions directed at their treatment in patients with advanced and chronic illnesses;
  2. Studying methods of improving communication between adults living with serious illness, their families and their health care providers;
  3. Evaluating models and systems of care for patients living with advanced illness and their families.

Applications due April 3, 2017

  The Role of Health Policy and Health Insurance in Improving Access to and Performance of Cancer Prevention, Early Detection, and Treatment Services (ACS) (Deadline: 4/3/17)

The Role of Health Policy and Health Insurance in Improving Access to and Performance of Cancer Prevention, Early Detection, and Treatment Services (ACS)

Purpose: A call for research that evaluates the impact of the many changes now occurring in the healthcare system with a particular focus on cancer prevention, control, and treatment. Efforts focusing on improving access to care may also impact inequities that contribute to health disparities. New health public policy initiatives such as the new federal and state marketplaces that have expanded insurance coverage, as well as Medicaid expansion in some states, create natural experiments ripe for evaluation. Research to be funded by this RFA should focus on the changes in national, state, and/or local policy and the response to these changes by healthcare systems, insurers, payers, communities, practices, and patients.

The association is keenly interested in supporting rapid learning research to study the effects of health policy changes on patients, providers, and health systems. This includes but is not limited to:

  • Facilitators and barriers to care;
  • Unintended consequences;
  • Differential experiences and outcomes of patients seeking or receiving care;
  • Best practice models for quality care; and,
  • Economic Impact

Applications due April 3, 2017

  Boehringer Ingelheim Pharma GmbH & Co. KG | Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) (Deadline: Continuous)

Boehringer Ingelheim Pharma GmbH & Co. KG | Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)

Medical Educational Grants are independent educational activities that utilize effective educational methods to address unmet medical needs that leads to improved patient outcomes. A Boehringer Ingelheim Pharmaceuticals, Inc. medical educational grant is designed to provide support for accredited educational programs for health care providers and non-accredited educational programs directed toward the patient and the local health care community.

The Medical Education Grants Department consists of education professionals who facilitate lifelong learning for clinicians and patients through support of independent education. BIPI's Medical Education and Research Grants department is committed to supporting innovative, high quality, independent medical education and research for healthcare professionals and patients that resolves unmet medical needs, fosters clinical excellence, and measurably improves health outcomes in areas of strategic focus to BIPI.

The sponsor considers funding of activities in many therapeutic areas including:

  • Therapeutic Areas Cardiovascular Disease – Stroke Prevention in Atrial Fibrillation
  • Cardiovascular Disease – Venous Thromboembolism (VTE)
  • Immunology – General Immunology
  • Oncology – Acute Myeloid Leukemia (AML)
  • Oncology – Lung Cancer
  • Respiratory Disease – Chronic Obstructive Pulmonary Disease (COPD)
  • Respiratory Disease – Interstitial Lung Disease (ILD)

Funding may be limited or exhausted in some therapeutic areas. BIPI will review and consider support of those requests in the areas above. To that end, educational objectives have been identified that are derived from evidence based science and are intended to close gaps in research, knowledge, or behaviors that represent barriers in care and patient outcomes.

Deadline continuous

  Sanofi-Aventis U.S. Inc. Education Grants (Deadline continuous)

Sanofi-Aventis U.S. Inc. Education Grants

Sanofi US is committed to funding high quality educational activities and materials in the therapeutic areas of interest to the company that have the potential to improve patient care and health outcomes.

The purpose of an educational grant is to support an activity that encourages an educational interchange with respect to available scientific and medical information. Educational activities may or may not be accredited.

Educational Grants fund educational activities and materials designed to improve the knowledge, competence (skill) and/or performance of healthcare professionals, patients, and/or consumers for improved patient care and outcomes.

Grants may be given for live educational activities, as well as educational publications and other types of enduring materials (e.g. interactive web, CD rom, audio tapes, etc.) provided that the activities or materials are advertised and open to a broad audience beyond members of the requesting institution. Fellowships or career development awards may be considered in limited circumstances.

Applicant must select one of the following Therapeutic Areas:

  • Cardiovascular
  • Diabetes
  • Genetic Diseases
  • Immunology
  • Multiple Sclerosis
  • Oncology
  • Orthopedics
  • Renal
  • Thyroid Cancer
  • Transplantation

Deadline continuous

Top